VITA 34 AG Stock

Equities

V3V

DE000A0BL849

Healthcare Facilities & Services

Real-time Estimate Tradegate 07:30:00 2024-04-16 am EDT 5-day change 1st Jan Change
4.56 EUR -0.87% Intraday chart for VITA 34 AG +0.44% -13.36%
Sales 2023 * 76.8M 81.71M Sales 2024 * 79.1M 84.15M Capitalization 80.19M 85.31M
Net income 2023 * -4M -4.26M Net income 2024 * -2M -2.13M EV / Sales 2023 * 1.2 x
Net Debt 2023 * 12M 12.77M Net Debt 2024 * 6.6M 7.02M EV / Sales 2024 * 1.1 x
P/E ratio 2023 *
-19.2 x
P/E ratio 2024 *
-38.3 x
Employees 815
Yield 2023 *
-
Yield 2024 *
-
Free-Float 30.42%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.87%
1 week+0.44%
Current month-8.84%
1 month+5.09%
3 months-12.02%
6 months+0.89%
Current year-13.36%
More quotes
1 week
4.48
Extreme 4.48
5.00
1 month
4.21
Extreme 4.21
5.90
Current year
3.69
Extreme 3.69
5.90
1 year
3.69
Extreme 3.69
7.32
3 years
3.69
Extreme 3.69
17.95
5 years
3.69
Extreme 3.69
17.95
10 years
3.55
Extreme 3.551
18.20
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 22-03-21
Director of Finance/CFO - 22-07-31
Investor Relations Contact - -
Members of the board TitleAgeSince
Director/Board Member 49 20-06-30
Chairman 59 21-12-14
Director/Board Member 51 -
More insiders
Date Price Change Volume
24-04-16 4.54 -1.30% 1 500
24-04-15 4.6 -3.77% 2,913
24-04-12 4.78 +3.46% 512
24-04-11 4.62 +2.21% 512
24-04-10 4.52 0.00% 512

Delayed Quote Xetra, April 16, 2024 at 06:19 am EDT

More quotes
Vita 34 International AG is a Germany-based company engaged in the medical technology sector. The Company is involved in the long-term storage and processing of stem cells from human umbilical cord blood. The cells are collected at the child’s birth and can be used later in his or her life for the treatment of many diseases, such as anemia, diabetes, degenerative joint diseases, cancer, neurological deficits after brain injuries, cartilage damages and others. They also allow the growing of whole organs, such as the liver. On average, one out seven individuals, whose cells are stored, receives autologous stem cell transplant by the age of 70. The Company acts as a cord blood bank and is also engaged in research activities in the area of regenerative medicine, including curing the consequences of strokes and heart attacks. The Company operates in Germany, Spain and Denmark.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
4.6 EUR
Average target price
5.3 EUR
Spread / Average Target
+15.22%
Consensus

Quarterly revenue - Rate of surprise